ArticlemSphere2020
Controlling the Growth of the Skin Commensal Staphylococcus epidermidis Using d-Alanine Auxotrophy.
Article in mSphere, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Metabolic shifts driven by host-microbial interactions.The FEBS journal · 2026Review
- Metabolic and regulatory adaptations of Staphylococcus epidermidis to host stresses.FEMS microbiology reviews · 2026Review
- Skin Protection Effects of Lactobacillus paragasseri HN910 Lysate and the Role of Alanine.Probiotics and antimicrobial proteins · 2026Article
- The human skin microbiome: from metagenomes to therapeutics.Nature reviews. Microbiology · 2025Review
- Using a full thickness bioengineered human skin equivalent as a model for radiation biology research.Scientific reports · 2025Article
- Skin microbiota in atopic dermatitis: victim or executioner?Clinical microbiology reviews · 2025Review
- Beneficial perspective onFrontiers in immunology · 2025Review
- Advances in Microbiome-Based Therapeutics for Dermatological Disorders: Current Insights and Future Directions.Experimental dermatology · 2024Review
- Transient infection ofApplied and environmental microbiology · 2024Article
- Feasibility of engineeredBioengineering & translational medicine · 2024Article
- Recent advances in single-cell engineered live biotherapeutic products research for skin repair and disease treatment.NPJ biofilms and microbiomes · 2023Review
- Article
- Staphylococcus epidermidis and its dual lifestyle in skin health and infection.Nature reviews. Microbiology · 2023Review
- Engineering a "detect and destroy" skin probiotic to combat methicillin-resistant Staphylococcus aureus.PloS one · 2022Article
- Development of synthetic biotics as treatment for human diseases.Synthetic biology (Oxford, England) · 2021Review
- The skin microbiome: from historical ecology to therapeutic frontiers.Anais brasileiros de dermatologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Using live microbes as therapeutic candidates is a strategy that has gained traction across multiple therapeutic areas. In the skin, commensal microorganisms play a crucial role in maintaining skin barrier function, homeostasis, and cutaneous immunity. Alterations of the homeostatic skin microbiome are associated with a number of skin diseases. Here, we present the design of an engineered commensal organism,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.